Amy Burroughs
Directeur Général chez TERNS PHARMACEUTICALS, INC.
Fortune : 255 737 $ au 30/04/2024
Profil
Ms. Amy L.
Burroughs is a Chief Executive Officer & Director at Terns Pharmaceuticals, Inc., an Independent Director at Tenaya Therapeutics, Inc. and a Chief Medical Officer at Eluminex Biosciences Ltd.
She is on the Board of Directors at Terns Pharmaceuticals, Inc., Tenaya Therapeutics, Inc. and Cleave Therapeutics, Inc. Ms. Burroughs was previously employed as an Independent Director by DiaMedica Therapeutics, Inc., a Chief Commercial Officer by APT Pharmaceuticals, Inc., a Principal by ePhysician, Inc., a Commercial Team Leader by Genentech, Inc., a Principal by Procter & Gamble Co., and a Principal by WholeHealth Living, Inc. She received her undergraduate degree from Dartmouth College and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2022 | 56 132 ( inf% ) | 142 014 $ | 30/04/2024 | |
| 03/01/2023 | 44 950 ( 0,12% ) | 113 724 $ | 30/04/2024 |
Postes actifs de Amy Burroughs
| Sociétés | Poste | Début |
|---|---|---|
| TENAYA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/12/2022 |
| TERNS PHARMACEUTICALS, INC. | Directeur Général | 07/02/2024 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/04/2019 |
Eluminex Biosciences Ltd.
 Eluminex Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Eluminex Biosciences Ltd. is a Chinese clinical-stage biotechnology company that focuses on the development and commercialization of innovative therapeutics for ophthalmic diseases. Eluminex's headquarters and research and development center are located in Biobay Industrial Park, with a US-subsidiary located in the area. The private company has developed a pipeline of next-generation protein therapeutics for retinal diseases, including age-related macular degeneration, macular edema, and diabetic retinopathy. The company is devoted to innovating the next generation of first-in-class or ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. Eluminex has exclusively licensed rights for the development and commercialization of an investigational clinical-stage biosynthetic cornea derived from recombinant human collagen type III for the treatment of corneal blindness. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Amy Burroughs
| Sociétés | Poste | Fin |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/03/2023 |
ePhysician, Inc.
 ePhysician, Inc. Packaged SoftwareTechnology Services ePhysician, Inc. developed point-of-care software products. The company was headquartered in Mountain View, CA. | Corporate Officer/Principal | - |
WholeHealth Living, Inc.
 WholeHealth Living, Inc. Medical/Nursing ServicesHealth Services WholeHealth Living, Inc. perates outpatient healthcare facilities. It is an internet-enabled provider of integrative health care solutions for managed care organizations, health plans, practitioners, wellness, fitness centers and consumers (patients). The company was founded in 1988 and is headquartered in Sterling, VA. | Corporate Officer/Principal | - |
APT Pharmaceuticals, Inc.
 APT Pharmaceuticals, Inc. BiotechnologyHealth Technology APT Pharmaceuticals, Inc. operated as a drug development company. The company was founded on December 15, 1999 and was headquartered in Burlingame, CA. | Corporate Officer/Principal | - |
| PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formation de Amy Burroughs
| Dartmouth College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| TENAYA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
APT Pharmaceuticals, Inc.
APT Pharmaceuticals, Inc. BiotechnologyHealth Technology APT Pharmaceuticals, Inc. operated as a drug development company. The company was founded on December 15, 1999 and was headquartered in Burlingame, CA. | Health Technology |
WholeHealth Living, Inc.
WholeHealth Living, Inc. Medical/Nursing ServicesHealth Services WholeHealth Living, Inc. perates outpatient healthcare facilities. It is an internet-enabled provider of integrative health care solutions for managed care organizations, health plans, practitioners, wellness, fitness centers and consumers (patients). The company was founded in 1988 and is headquartered in Sterling, VA. | Health Services |
ePhysician, Inc.
ePhysician, Inc. Packaged SoftwareTechnology Services ePhysician, Inc. developed point-of-care software products. The company was headquartered in Mountain View, CA. | Technology Services |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Eluminex Biosciences Ltd.
Eluminex Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Eluminex Biosciences Ltd. is a Chinese clinical-stage biotechnology company that focuses on the development and commercialization of innovative therapeutics for ophthalmic diseases. Eluminex's headquarters and research and development center are located in Biobay Industrial Park, with a US-subsidiary located in the area. The private company has developed a pipeline of next-generation protein therapeutics for retinal diseases, including age-related macular degeneration, macular edema, and diabetic retinopathy. The company is devoted to innovating the next generation of first-in-class or ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. Eluminex has exclusively licensed rights for the development and commercialization of an investigational clinical-stage biosynthetic cornea derived from recombinant human collagen type III for the treatment of corneal blindness. | Health Technology |